Capricor Therapeutics (NASDAQ: CAPR) reported Q1 EPS of ($0.17), $0.02 worse than the analyst estimate of ($0.15). Revenue for the quarter came in at $880.81 thousand versus the consensus estimate of $900 thousand.

For earnings history and earnings-related data on Capricor Therapeutics (CAPR) click here.